The light at the end of the tunnel
January 1, 2024 DOI: 10.26481/dis.20241104jr via OpenAlex
Summary
The research examined the psychedelic effects and safety of Mebufotenin (5-MeO-DMT), finding that higher doses led to stronger effects and better clinical outcomes for patients with treatment-resistant depression. In two studies, one with healthy volunteers and another with patients suffering from depression, it was shown that these profound experiences were linked to significant reductions in depressive symptoms while remaining safe and well tolerated.
Study at a glance
| Population | healthy volunteers and patients with treatment-resistant depression |
|---|---|
| Key finding | Higher doses of vaporized 5-MeO-DMT elicited stronger effects and were associated with better clinical efficacy in reducing depressive symptoms. |
Abstract
The research described in this thesis focused on the psychedelic and psychoactive effects of the psychedelic drug Mebufotenin (5-MeO-DMT), as well as its safety and therapeutic efficacy. A prominent feature of 5-MeO-DMT is its ability to elicit a psychedelic state, which has been linked to feelings of profoundness and meaningfulness. This state, sometimes referred to as a mystical or peak experience, has been linked to therapeutic effects in patients with anxiety or depression. Two clinical studies were conducted, in which a vaporized 5-MeO-DMT formulation was first delivered to healthy volunteers and, in the second study, to patients with treatment-resistant depression (TRD), in order to assess safety and efficacy. Results indicated that higher doses, eliciting stronger and more profound effects, were related to better clinical efficacy in reducing depressive symptoms, while still being well tolerated and safe.